The Real Costs of the New Alzheimer’s Drug, Most of Which Will Fall to Taxpayers
(By Arthur Allen for KFF Health News) The first drug purporting to slow the advance of Alzheimer’s disease is likely
Read More
FDA
An experimental Alzheimer’s drug outperforms one just approved by the FDA
(By Jon Hamilton for NPR) Patients in the early stages of Alzheimer’s may soon have a new option to stave
Read MoreStatement: Broader Medicare Coverage of Leqembi Available Following FDA Traditional Approval
(Source – www.cms.gov/newsroom) Broader Medicare coverage is now available for Biogen and Eisai’s Leqembi (the brand name for lecanemab) following
Read MoreAn Alzheimer’s drug is on the way, but getting it may still be tough. Here’s why
(By Jon Hamilton for NPR) The first drug shown to slow down Alzheimer’s disease is likely to receive full approval
Read MoreTransforming Medicare Coverage: A New Medicare Coverage Pathway for Emerging Technologies and Revamped Evidence Development Framework
(Source – www.cms.gov) The Centers for Medicare & Medicaid Services (CMS) is committed to fostering innovation while ensuring that people
Read MoreDrugmakers Are Abandoning Cheap Generics, and Now US Cancer Patients Can’t Get Meds
(By Arthur Allen for KFF Health News) On Nov. 22, three FDA inspectors arrived at the sprawling Intas Pharmaceuticals plant
Read MoreSome cancer drugs are in short supply, putting patients’ care at risk. Here’s why
(By Yuki Noguchi for NPR) Toni Dezomits is used to facing death. She served in the Gulf War and later
Read MoreFDA approves Pfizer’s RSV vaccine for older adults
(By Helen Branswell for STAT) The Food and Drug Administration approved a second vaccine to protect older adults against RSV
Read MoreScience finally figured out how to make effective RSV vaccines. Will seniors care?
(By Helen Branswell for STAT) The world has waited decades for vaccines to protect older adults against RSV. One, made
Read MoreHow Medicare’s Aduhelm decision revived old questions about new drugs
(By Kerry Dooley Young for STAT) Medicare’s decision to withhold coverage for Biogen’s Aduhelm despite the Food and Drug Administration’s
Read More